Your AI-Trained Oncology Knowledge Connection!

Recent Updates in The Role of Immunotherapies in Early NSCLC: Translating Evidence to Clinical Practice : Episode 1

Video

June 23, 2023

Overview of Early-Stage NSCLC and Molecular Testing

Author(s):

A panel of experts who treat patients with non-small cell lung cancer provides an overview of staging, molecular testing and treatment options in stage I-IIIB non-small cell lung cancer.

Now Viewing

EP: 1.Overview of Early-Stage NSCLC and Molecular Testing

EP: 2.Selecting Optimal Treatment in Early-Stage NSCLC

EP: 3.Neoadjuvant Therapy in Early-Stage NSCLC: CheckMate-816 Study

EP: 4.Perioperative Treatment in Early-Stage NSCLC: AEGEAN Study

EP: 5.Perioperative Treatment in Early NSCLC: KEYNOTE-671 and NEOTORCH Studies

EP: 6.Neoadjuvant Versus Perioperative Therapy in Resectable NSCLC

EP: 7.Neoadjuvant Versus Adjuvant Therapy in Resectable NSCLC

EP: 8.Adjuvant Therapy in NSCLC: IMPower-010 and KEYNOTE-091 Studies

EP: 9.Treatment Strategy in Patients with Unresectable Stage I-III NSCLC

EP: 10.Consolidation Immunotherapy in Unresectable Early NSCLC: PACIFIC Study

EP: 11.Consolidation Immunotherapy in Unresectable Early NSCLC: Novel Approaches

EP: 12.Treatment for Patients Unsuitable for or Refractory to Consolidation Durvalumab

EP: 13.Practice Pearls for Community Oncologists Treating Early-Stage NSCLC

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All

Video

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Apr 23rd 2025 - Apr 24th 2026

online-activity

Video

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Apr 23rd 2025 - Apr 24th 2026

online-activity

Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity

Latest Conference Coverage

Oncology Experts Preview Top Abstracts From AUA 2025

Future of Bispecifics and CAR T in R/R MM

Choosing Between Bispecifics and CAR T: Real-World Implications in R/R MM

Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

Overview of Early-Stage NSCLC and Molecular Testing

EP: 1.Overview of Early-Stage NSCLC and Molecular Testing

EP: 2.Selecting Optimal Treatment in Early-Stage NSCLC

EP: 3.Neoadjuvant Therapy in Early-Stage NSCLC: CheckMate-816 Study

EP: 4.Perioperative Treatment in Early-Stage NSCLC: AEGEAN Study

EP: 5.Perioperative Treatment in Early NSCLC: KEYNOTE-671 and NEOTORCH Studies

EP: 6.Neoadjuvant Versus Perioperative Therapy in Resectable NSCLC

EP: 7.Neoadjuvant Versus Adjuvant Therapy in Resectable NSCLC

EP: 8.Adjuvant Therapy in NSCLC: IMPower-010 and KEYNOTE-091 Studies

EP: 9.Treatment Strategy in Patients with Unresectable Stage I-III NSCLC

EP: 10.Consolidation Immunotherapy in Unresectable Early NSCLC: PACIFIC Study

EP: 11.Consolidation Immunotherapy in Unresectable Early NSCLC: Novel Approaches

EP: 12.Treatment for Patients Unsuitable for or Refractory to Consolidation Durvalumab

EP: 13.Practice Pearls for Community Oncologists Treating Early-Stage NSCLC

Newsletter

Latest CME

Addressing Unmet Needs in HER2+ Metastatic BTC

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Addressing Unmet Needs in HER2+ Metastatic BTC

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Addressing Unmet Needs in HER2+ Metastatic BTC

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Latest Conference Coverage